سعر جيوتريف 30 مجم 28 قرصًا مغلفًا 2026

Afatinib 30 mg film-coated tablets, pack of 28 (Giotrif), Boehringer Ingelheim distributed in Egypt via Egyptian Pharmaceutical Trading Company. Irreversible ErbB family blocker for EGFR-mutation-positive NSCLC and squamous NSCLC after platinum chemotherapy (per US/EU labelling of the same molecule/brand family).

• First-line treatment of metastatic NSCLC whose tumours have non-resistant EGFR mutations as detected by an approved test (limitations: not established for resistant EGFR mutations).Population: AdultsDailyMed (NLM)
• Treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy.Population: AdultsDailyMed (NLM)
• EGFR TKI-naïve adults with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and adults with locally advanced or metastatic squamous NSCLC progressing on or after platinum-based chemotherapy (monotherapy).Population: AdultsMHRA / emc

• Most common (≥20%): diarrhoea, rash/acneiform dermatitis, stomatitis, paronychia, dry skin, decreased appetite, nausea, vomiting, pruritus (US).International label, same formulation · DailyMed (NLM)

• None listed in the US GILOTRIF prescribing information section 4.International label, same formulation · DailyMed (NLM)
• Hypersensitivity to afatinib or to any of the excipients (UK SmPC).International label, same product · MHRA / emc

• Diarrhoea may cause dehydration and renal failure; withhold for severe/prolonged diarrhoea; provide antidiarrhoeal at onset.International label, same formulation · DailyMed (NLM)
• Bullous and exfoliative skin disorders; discontinue for life-threatening cutaneous reactions (including possible SJS/TEN).International label, same formulation · DailyMed (NLM)
• Interstitial lung disease (ILD) ~1.6%; withhold for acute/worsening pulmonary symptoms; discontinue if ILD confirmed.International label, same formulation · DailyMed (NLM)

• P-gp inhibitors (e.g. ritonavir, cyclosporine, ketoconazole, itraconazole, erythromycin, verapamil, amiodarone)MajorCan increase afatinib exposure; US: reduce GILOTRIF by 10 mg/day if not tolerated. UK: stagger P-gp inhibitor dosing (preferably 6 or 12 hours apart).DailyMed (NLM), MHRA / emc
• P-gp inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, St John's wort)MajorCan decrease afatinib exposure; US: increase by 10 mg/day as tolerated for chronic inducers.DailyMed (NLM)

• Can cause fetal harm based on animal data and mechanism; advise pregnant women of potential fetal risk (US). Insufficient human data (UK).International label, same formulation · DailyMed (NLM)
• Advise women not to breastfeed during treatment and for 2 weeks after the final dose (US). UK: advise against breastfeeding while receiving Giotrif.International label, same formulation · DailyMed (NLM), MHRA / emc

• Afatinib: Covalently binds EGFR (ErbB1), HER2 (ErbB2) and HER4 (ErbB4) kinase domains, irreversibly inhibiting tyrosine kinase autophosphorylation and downregulating ErbB signalling.